Sotera Health LLC announces intent to sell Nordion#s Medical Isotopes segment to BWXT

Food and Healthcare Press Releases Wednesday April 18, 2018 08:06
BROADVIEW HEIGHTS, Ohio--18 Apr--PRNewswire/InfoQuest
Sotera Health committed to Safeguarding Global Health(TM) with Nordion's increased focus on global gamma technologies business

Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced that it has entered into a definitive asset purchase agreement to sell the Medical Isotopes segment of its Nordion business to a subsidiary of BWX Technologies, Inc. (BWXT). This transaction will create a platform that will accelerate growth for both companies.

"The world's need for gamma technology has expanded dramatically as the demand for sterilization of medical and non-medical applications has accelerated in response to increasing global regulatory demands and growing healthcare needs," said Michael Petras, Chief Executive Officer of Sotera Health. "The sale will enable BWXT to enter the medical isotope field with highly skilled employees and specialized facilities that are recognized as the best in the business. As the world's only fully integrated provider of mission-critical services to the healthcare industry, Sotera Health is excited about the additional value Nordion will bring to our gamma customers, and our other best-in-class businesses, Sterigenics and Nelson Labs."

Through the agreement, BWXT will acquire essentially all of Nordion's medical isotope assets, including the radiochemical operation and contract manufacturing services in Kanata, and the medical isotope operation in Vancouver, British Columbia.

Both companies will continue to operate from Nordion's state-of-the-art licensed facility in Kanata, Ontario. Approximately 150 employees will transition to BWXT at the close of the sale.

"Nordion will continue to focus on accelerating growth in gamma technologies, including industrial and medical cobalt-60 which fits perfectly with Sotera Health's broader mission of Safeguarding Global Health(TM)," said Kevin Brooks, President of Nordion.

About Sotera Health:

Sotera Health LLC, along with its business entities, is the world's leading, fully integrated protector of global health. With over 500 years of combined scientific expertise, the company ensures the safety of healthcare by providing mission-critical services to the medical device, pharmaceutical, tissue and food industries. Sotera Health operates more than 61 facilities in 13 countries. The company has over 2,600 employees globally and touches the lives of more than 180 million people around the world each year. Sotera Health serves more than 5,000 customers worldwide including 75 of the top 100 medical device manufacturers.

Sotera Health goes to market through its three best-in-class companies – Nelson Labs(TM) ,   Nordion(R) and   Sterigenics(R) - with the mission of ensuring the safety of healthcare each and every day. Nelson Labs offers microbiological and analytical testing and consultancy to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and the pharmaceutical and biologics fields.   Nordion is the world's largest provider of Cobalt-60 used in the gamma sterilization process as well as medical isotopes used in the diagnosis and treatment of various diseases and cancers. Sterigenics provides comprehensive contract sterilization and ionization solutions for the medical device, pharmaceutical, food safety and high-performance materials industries.

Sotera Health LLC is owned by private equity firms Warburg Pincus and GTCR.   Learn more about Sotera Health at soterahealth.com, about Nelson Labs at nelsonlabs.com, about Nordion at nordion.com and about Sterigenics at sterigenics.com.

Contacts:
Paul Monlezun
Public Affairs Advisors
613-222-7184
paul.monlezun@publicaffairsadvisors.com
Kristin A. Gibbs
Chief Marketing Officer
Sotera Health LLC
kgibbs@soterahealth.com
440-262-1412

Latest Press Release

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in...

UK Schools Rank Last in Providing Oral Health Education, FDI Survey of 13 Countries Says

Today on World Oral Health Day (WOHD), FDI World Dental Federation (FDI) released the results of a survey from 13 countries, which asked parents with children aged 5–16 if their child's school provided lessons on good oral care. Poor oral health...

Merck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology

- Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to...

Oxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment

Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing...

FDI: Endodontics White Paper Calls for Treatment to Consider Impact on Patient Health and Well-being

FDI World Dental Federation (FDI) released its first white paper on endodontic care today, providing an important resource for dentists, national dental associations (NDAs) and other oral health actors. (Logo:...

Related Topics